✦ LIBER ✦

Nodular non-Hodgkin's lymphoma (NHL): Factors influencing prognosis and indications for aggressive treatment

✍ Scribed by Richard A. Rudders; Mona Kaddis; Ronald A. Delellis; Henry Casey Jr.

Publisher: John Wiley and Sons
Year: 1979
Tongue: English
Weight: 619 KB
Volume: 43
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197905)43:5<1643::aid-cncr2820430513>3.0.co;2-j

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Nodular histiocytic lymphoma: Factors in

Nodular histiocytic lymphoma: Factors influencing prognosis and implications for aggressive chemotherapy

✍ John H. Glick; Eleanor McFadden; William Costello; Ediz Ezdinli; Costan W. Berar 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 513 KB

Late relapse with nodular lymphoma after

Late relapse with nodular lymphoma after treatment for diffuse non-Hodgkin's lymphoma

✍ M. Marazuela; M. Yebra; J. A. Girón; J. L. Menéndez; J. A. Vargas; P. España; M. 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Histologic conversion from a low-grade non-Hodgkin's lymphoma (NHL) into a more aggressive histologic pattern is a common, well-documented event in NHL. The converse phenomenon, appearance of a low-grade, follicular NHL after treatment for diffuse, intermediate, or high-grade NHL, has only recently

Gemcitabine-based combination chemothera

Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma

✍ Shih-Hung Yang; Zhong-Zhe Lin; Sung-Hsin Kuo; Ann-Lii Cheng 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 418 KB 👁 1 views

Clinical pretreatment risk factors and G

Clinical pretreatment risk factors and Ga-67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non-Hodgkin lymphoma

✍ Ora Israel; Maya Mor; Ron Epelbaum; Alex Frenkel; Nissim Haim; Eldad J. Dann; Di 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

Chemotherapy followed by consolidation r

Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage ii aggressive histologic type non-hodgkin's lymphoma

✍ Michael J. O'Connell; David P. Harrington; John D. Earle; Gerhard J. Johnson; Jo 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 509 KB

Sixty-three eligible patients with Ann Arbor clinical Stage I1 or IIE aggressive histologic type non-Hodgkin's lymphomas received combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone (COPAJ) as the primary treatment technique. Moderate-dose radiation therapy (2500 to

Combined chemotherapy with carmustine, d

Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma : A long-term follow-up study

✍ Luigi Rigacci; Valentina Carrai; Luca Nassi; Renato Alterini; Giovanni Longo; Fr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views